Government to support Chong Kun Dang’s dyslipidemia drug development

Published: 2013-03-18 06:56:00

Updated: 2013-03-18 06:56:00

Chong Kun Dang Pharmaceutical said last Monday it has signed an agreement with the state-run Korea Drug Development Fund (KDDF).

The company plans to carry out clinical trials for its dyslipidemia drug candidate as part of the KDDF program to cultivate blockbuster drugs, targeting the global m...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK